Survival TRaining for ENhancing Total Health (STRENGTH)
NCT ID: NCT00068458
Last Updated: 2017-12-19
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
39 participants
INTERVENTIONAL
2003-09-30
2005-01-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
PURPOSE: This randomized phase II trial is studying the effectiveness of three home-based diet and/or exercise programs in preventing weight gain and loss of muscle tissue in women who are receiving chemotherapy for stage I, stage II, or stage IIIA breast cancer.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
* Compare the efficacy of exercise alone or combined with a modified diet as home-based interventions to prevent increases in body fat during adjuvant chemotherapy in women with stage I, II, or IIIA breast cancer.
* Compare the efficacy of these regimens, in terms of reducing gains in adipose tissue, reducing losses in absolute amounts of lean body tissue, reducing gains in weight, influencing levels of biomarkers associated with the risk of breast cancer and/or other comorbid conditions, improving self-efficacy for exercise behaviors, reducing depression, and improving quality of life in these patients.
* Compare the adherence rates to these regimens in these patients.
* Determine the associations between study condition and adherence and change in endpoints in patients treated with these regimens.
* Determine the feasibility of conducting home-based exercise and diet studies using the infrastructure of the cooperative group.
OUTLINE: This is a pilot, randomized, multicenter study. Patients are stratified according to body mass index (no more than 25 kg/m\^2 vs more than 25 kg/m\^2), race (white vs non-white), and prior exercise history (vigorous exercise of at least 30 minutes, 3 times a week prior to diagnosis) (yes vs no). Patients are randomized to 1 of 3 treatment arms.
* Arm I (calcium-rich diet): Patients receive materials and counseling to promote a diet that contains ample amounts of calcium (1,200-2,500 mg/day).
* Arm II (calcium-rich diet and exercise): Patients receive materials and counseling as in arm I and instruction and materials to promote strength training and endurance exercises.
* Arm III (calcium-rich, high fruit and vegetable, low-fat diet and exercise): Patients receive materials and counseling as in arm II and materials and counseling to consume at least 5 servings of vegetables and fruit per day and limit fat intake to less than 20% of total calories.
In all arms, patients continue regimens for 6 months.
Measurements of body composition, weight, waist circumference, serum levels of insulin, insulin-like growth factor, sex hormone-binding globulin, and total cholesterol are obtained at baseline and 6 months.
Quality of life, depression, diet composition, and physical activity are assessed at baseline and at 3 and 6 months.
Patients are followed at 1 month.
PROJECTED ACCRUAL: A total of 90 patients (30 per treatment arm) will be accrued for this study within 16 months.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
OTHER
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Arm 1: calcium diet
Calcium-Rich Diet (dietary counseling + materials promoting an intake of 1,200 - 2,500 mg/day).
Calcium-Rich Diet
1,200 - 2,500 mg/day. 6 month intervention
Arm 2: Exercise + Calcium-Rich Diet
Exercise + Calcium Rich Diet (dietary counseling + materials promoting strength training and aerobic activity + a calcium intake of 1,200 - 2,500 mg/day).
Arm 2: Exercise + Calcium-Rich Diet
Dietary counseling + material promoting strength training an aerobic activity + a calcium intake of 1,200 - 2,500 mg/day. 6 month intervention.
Exercise + Fruit & Vegetable, Low Fat + Calcium Diet
Dietary counseling + materials promoting strength training and aerobic activity + a diet that has \< 20% of energy coming from fat and intakes of fruits and vegetables of \> 5 servings/day + a calcium intake of 1,200 - 2,500 mg/day. 6 month intervention.
Exercise + Fruit & Vegetable, Low Fat + Calcium Diet
1,200 - 2,500 Calcium intake per day. 6 month intervention period.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Calcium-Rich Diet
1,200 - 2,500 mg/day. 6 month intervention
Arm 2: Exercise + Calcium-Rich Diet
Dietary counseling + material promoting strength training an aerobic activity + a calcium intake of 1,200 - 2,500 mg/day. 6 month intervention.
Exercise + Fruit & Vegetable, Low Fat + Calcium Diet
1,200 - 2,500 Calcium intake per day. 6 month intervention period.
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Histologically confirmed breast cancer
* Stage I, II, or IIIA
* Scheduled to receive adjuvant chemotherapy OR received 1 prior course of chemotherapy
* Hormone receptor status:
* Not specified
PATIENT CHARACTERISTICS:
Age
* 18 and over
Sex
* Female
Menopausal Status
* Premenopausal, defined as at least 1 of the following:
* Less than 4 months since last menstrual period at diagnosis
* Follicle-stimulating hormone level in the premenopausal range
Performance status
* Not specified
Life expectancy
* Not specified
Hematopoietic
* Not specified
Hepatic
* Not specified
Renal
* No calcium-based kidney stones
Cardiovascular
* No angina within the past 6 months
* No myocardial infarction within the past 6 months
* No abnormal MUGA and/or stress test
Other
* Not pregnant or nursing
* Access to a telephone
* Able to read and speak English
* No other prior or concurrent malignancy except curatively treated carcinoma in situ of the cervix or nonmelanoma skin cancer
* No history of hyperthyroidism or hypothyroidism
* No paralysis
* No osteoarthritis with uncontrolled joint pain that would preclude exercise
* No diverticulitis
* No serious medical or psychiatric illness that would preclude giving informed consent or completing study therapy or quality of life questionnaires
* No medical condition that would interfere with body composition assessment
* No medical condition for which unsupervised exercise is contraindicated
* No medical condition for which a high vegetable and fruit diet or a calcium-rich diet is contraindicated
PRIOR CONCURRENT THERAPY:
Biologic therapy
* Not specified
Chemotherapy
* See Disease Characteristics
Endocrine therapy
* Not specified
Radiotherapy
* Not specified
Surgery
* No prior bilateral oophorectomy
* No prior amputation
* No concurrent transverse rectus abdominis myocutaneous surgery
* No concurrent surgery
Other
* No concurrent blood-thinners (e.g., coumadin or warfarin)
18 Years
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
National Cancer Institute (NCI)
NIH
Duke University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Edward G. Shaw, MD
Role: STUDY_CHAIR
Wake Forest University Health Sciences
Wendy Demark-Wahnefried, PhD
Role: PRINCIPAL_INVESTIGATOR
Duke Cancer Institute
Roger T. Anderson, PhD
Role: STUDY_CHAIR
Wake Forest University Health Sciences
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Duke Comprehensive Cancer Center
Durham, North Carolina, United States
Southeastern Medical Oncology Center
Goldsboro, North Carolina, United States
Comprehensive Cancer Center at Wake Forest University
Winston-Salem, North Carolina, United States
Cancer Centers of the Carolinas - Eastside
Greenville, South Carolina, United States
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.